TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,313.20▼ 0.75%TCS₹2,298.00▲ 2.08%HDFCBANK₹725.05▼ 6.76%ICICIBANK₹1,411.90▼ 3.31%INFY₹1,130.00▲ 3.95%HINDUNILVR₹2,028.00▼ 5.22%ITC₹271.65▼ 3.91%SBIN₹1,048.00▼ 1.13%BHARTIARTL₹1,941.70▼ 0.34%KOTAKBANK₹397.35▲ 4.00%LT₹4,081.00▲ 6.31%AXISBANK₹1,251.00▼ 0.40%ASIANPAINT₹2,625.20▼ 2.50%MARUTI₹13,809.00▲ 2.18%AAPL$317.61▼ 2.75%MSFT$481.14▲ 19.60%GOOGL$341.22▼ 3.06%AMZN$261.20▲ 4.48%NVDA$218.03▲ 7.26%META$544.51▼ 15.69%TSLA$341.10▼ 7.70%BRK-B$499.37▲ 1.65%JPM$357.57▲ 5.52%V$368.75▲ 2.27%
RELIANCE₹1,313.20▼ 0.75%TCS₹2,298.00▲ 2.08%HDFCBANK₹725.05▼ 6.76%ICICIBANK₹1,411.90▼ 3.31%INFY₹1,130.00▲ 3.95%HINDUNILVR₹2,028.00▼ 5.22%ITC₹271.65▼ 3.91%SBIN₹1,048.00▼ 1.13%BHARTIARTL₹1,941.70▼ 0.34%KOTAKBANK₹397.35▲ 4.00%LT₹4,081.00▲ 6.31%AXISBANK₹1,251.00▼ 0.40%ASIANPAINT₹2,625.20▼ 2.50%MARUTI₹13,809.00▲ 2.18%AAPL$317.61▼ 2.75%MSFT$481.14▲ 19.60%GOOGL$341.22▼ 3.06%AMZN$261.20▲ 4.48%NVDA$218.03▲ 7.26%META$544.51▼ 15.69%TSLA$341.10▼ 7.70%BRK-B$499.37▲ 1.65%JPM$357.57▲ 5.52%V$368.75▲ 2.27%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ANIP

ANI Pharmaceuticals, Inc. - Common Stock

NASDAQ
$76.86
▼ $0.86 (-1.1%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 20 Aug 2026
H $87.76L $70.15-6.1%
$87.76$84.24$80.72$77.19$73.67$70.15$76.86
RSI (14)
Intraday · 15-minSell-15RSI 38SidewaysMACD Bearishfor day-trading context — not advice

Technical signal

Sell-20
RSI (14)45
oversold 30overbought 70
Trend
Downtrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$73.27
Resistance
$83.21
  • Price is below its 50-day average (medium-term weakness).
  • MACD just crossed bullish (momentum turning up).

Signal backtest · 2025-11-13 → 2026-08-20

Strategy return
-14.5%
Buy & hold
-9.1%
Trades
8
Win rate
25%

$100,000.00 invested would be worth $85,495.31 (-14.5%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About ANI Pharmaceuticals, Inc.· Drug Manufacturers - Specialty & Generic

source: yahoo

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
970
Headquarters
Baudette, United States
www.anipharmaceuticals.com ↗

Fundamentals

source: yahoo
Market cap
$1.77B
P/E
16.7
P/B
2.8
EPS
$4.59
Div yield
—
Profit margin
11.1%
ROE
20.5%
Debt / Equity
1.05
Beta
0.46
52-week range
$70.15 – $99.50
52-week low · $70.1523% of rangehigh · $99.50

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:▲ Positive3↑ · 1↓ · 4–
  • The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call— Neutral
    StockStory · 16 Aug 2026
  • Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks— Neutral
    StockStory · 15 Aug 2026
  • Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?▼ Negative
    Zacks · 14 Aug 2026
  • ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

▲ Positive
Zacks · 14 Aug 2026
  • ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript— Neutral
    Motley Fool · 14 Aug 2026
  • ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration▲ Positive
    StockStory · 11 Aug 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.